scholarly journals Low Incidence of Opioid-Induced Respiratory Depression Observed with Oliceridine Regardless of Age or Body Mass Index: Exploratory Analysis from a Phase 3 Open-Label Trial in Postsurgical Pain

2021 ◽  
Author(s):  
Marek Brzezinski ◽  
Gregory B. Hammer ◽  
Keith A. Candiotti ◽  
Sergio D. Bergese ◽  
Peter H. Pan ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Respiratory Depression ◽  
Body Mass ◽  
Exploratory Analysis ◽  
Open Label ◽  
Phase 3 ◽  
Postsurgical Pain ◽  
Open Label Trial ◽  
Low Incidence

Alirocumab efficacy and safety by body mass index: Pooled analysis from 10 Phase 3 ODYSSEY trials

2018 ◽  
Vol 275 ◽  
pp. e53-e54
Author(s):  
F. Tinahones ◽  
U. Laufs ◽  
B. Cariou ◽  
J. Yang ◽  
M.J. Louie ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Pooled Analysis ◽  
Efficacy And Safety ◽  
Phase 3

scholarly journals TO COMPARE THE EFFECT OF CHITOSAN, LIFESTYLE MODIFICATION, AND COMBINATION OF CHITOSAN AND LIFESTYLE MODIFICATION ON BODY MASS INDEX IN OBESE PATIENTS

2019 ◽  
pp. 230-233
Author(s):  
VASUNDHARA BHOPLE ◽  
DEEPAK BHOSLE
Keyword(s):  
Body Mass Index ◽  
Comparative Study ◽  
Body Mass ◽  
Lifestyle Modification ◽  
T Test ◽  
Pronounced Effect ◽  
Obese Patients ◽  
Open Label ◽  
Study Population ◽  
Pronounced Reduction

Objective: The objective of this study was to compare the effect of chitosan, lifestyle modification, and combination of chitosan and lifestyle modification on body mass index (BMI) in obese patients. Methods: A prospective, randomized, open-label comparative study conducted for the period of 24 weeks. The study population was enrolled in three groups (chitosan 500 mg BD, lifestyle modification, and chitosan 500 mg BD and lifestyle modification). Data were analyzed using “t”-test and ANOVA. Results: There is a reduction in BMI in all the three groups. However, when we combined chitosan and lifestyle modification, there is pronounced reduction in BMI, which is statistically significant (p<0.0001). Conclusions: Chitosan and lifestyle modification have more pronounced effect on reduction on BMI as compared to monotherapy alone.

scholarly journals Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment

2017 ◽  
Vol 64 (4) ◽  
pp. 449-456 ◽  
Author(s):  
Kumiko Hamano ◽  
Hiroshi Nishiyama ◽  
Akiko Matsui ◽  
Manaka Sato ◽  
Masakazu Takeuchi
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
High Age
Sign in / Sign up

Export Citation Format

Share Document